Schulz, V
In glycemic control trials in adults with type 2 diabetes mellitus (monotherapy and combination therapy) [see Clinical Studies (14.2, 14.3)], during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA))
Shorter cycles (4-6 weeks) are sometimes used for cutting phases or competition preparation, while longer cycles (12-16 weeks) suit individuals with significant fat loss goals
The PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genesall critical to how your body responds to semaglutide therapy
As of 2026, Wegovy (semaglutide) is a mature, mainstream option on the UK market for adults who need help to lose weight alongside diet, exercise, and behavioural support
Your doctor will help you determine the best option based on your specific health needs